Recent advances and future trends in the targeted therapy of metastatic gastric cancer (Q38199128)

30 August 2017

Recent advances and future trends in the targeted therapy of metastatic gastric cancer (English)

1 reference

30 August 2017

Salah-Eddin Al-Batran

series ordinal

1

1 reference

PubMed ID

24665840

30 August 2017

Dominique Werner

series ordinal

2

1 reference

PubMed ID

24665840

30 August 2017

language of work or name

1 reference

25 March 2014

1 reference

Expert Review of Gastroenterology & Hepatology

30 August 2017

1 reference

30 August 2017

8

1 reference

30 August 2017

5

1 reference

30 August 2017

555-569

1 reference

Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008

30 August 2017

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.902304

Gastric cancer pathology and underlying molecular mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.902304

Understanding the genetic basis of gastric cancer: recent advances.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.902304

HER 2/neu protein expression in colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.902304

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.902304

Trastuzumab emtansine for HER2-positive advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.902304

Trastuzumab-DM1 is highly effective in preclinical models of HER2-positive gastric cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.902304

Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.902304

Phase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer that progressed during prior trastuzumab therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.902304

Synergy between trastuzumab and pertuzumab for human epidermal growth factor 2 (Her2) from colocalization: an in silico based mechanism

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.902304

Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.902304

Southwest Oncology Group study S0413: a phase II trial of lapatinib (GW572016) as first-line therapy in patients with advanced or metastatic gastric cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.902304

Preclinical antitumor activity of BMS-599626, a pan-HER kinase inhibitor that inhibits HER1/HER2 homodimer and heterodimer signaling.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.902304

Antitumor activity of HM781-36B, an irreversible Pan-HER inhibitor, alone or in combination with cytotoxic chemotherapeutic agents in gastric cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.902304

Evaluation of the antitumor effects and mechanisms of PF00299804, a pan-HER inhibitor, alone or in combination with chemotherapy or targeted agents in gastric cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.902304

Novel targeted agents for gastric cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.902304

Tumor antigen-targeted, monoclonal antibody-based immunotherapy: clinical response, cellular immunity, and immunoescape

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.902304

Cetuximab plus oxaliplatin/leucovorin/5-fluorouracil in first-line metastatic gastric cancer: a phase II study of the Arbeitsgemeinschaft Internistische Onkologie (AIO).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.902304

Phase II study and biomarker analysis of cetuximab combined with modified FOLFOX6 in advanced gastric cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.902304

A prospective phase II study of cetuximab in combination with XELOX (capecitabine and oxaliplatin) in patients with metastatic and/or recurrent advanced gastric cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.902304

Phase II study of cetuximab in combination with cisplatin and docetaxel in patients with untreated advanced gastric or gastro-oesophageal junction adenocarcinoma (DOCETUX study).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.902304

Phase II study of cetuximab in combination with FOLFIRI in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma (FOLCETUX study).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.902304

Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.902304

Chemoradiotherapy with or without cetuximab in patients with oesophageal cancer (SCOPE1): a multicentre, phase 2/3 randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.902304

Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.902304

Phase I study of epirubicin, cisplatin and capecitabine plus matuzumab in previously untreated patients with advanced oesophagogastric cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.902304

Matuzumab plus epirubicin, cisplatin and capecitabine (ECX) compared with epirubicin, cisplatin and capecitabine alone as first-line treatment in patients with advanced oesophago-gastric cancer: a randomised, multicentre open-label phase II study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.902304

Phase II trial of erlotinib in gastroesophageal junction and gastric adenocarcinomas: SWOG 0127.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.902304

A phase II study of perioperative concurrent chemotherapy, gefitinib, and hyperfractionated radiation followed by maintenance gefitinib in locoregionally advanced esophagus and gastroesophageal junction cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.902304

Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.902304

A phase II study of capecitabine, oxaliplatin, and bevacizumab in the treatment of metastatic esophagogastric adenocarcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.902304

Phase II study of modified docetaxel, cisplatin, and fluorouracil with bevacizumab in patients with metastatic gastroesophageal adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.902304

A phase II study of bevacizumab, oxaliplatin, and docetaxel in locally advanced and metastatic gastric and gastroesophageal junction cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.902304

Multicenter phase II study of irinotecan, cisplatin, and bevacizumab in patients with metastatic gastric or gastroesophageal junction adenocarcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.902304

Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.902304

Multicenter phase II study of oxaliplatin and sorafenib in advanced gastric adenocarcinoma after failure of cisplatin and fluoropyrimidine treatment. A GEMCAD study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.902304

Phase II study of sorafenib in combination with docetaxel and cisplatin in the treatment of metastatic or advanced gastric and gastroesophageal junction adenocarcinoma: ECOG 5203.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.902304

Phase II study of sunitinib as second-line treatment for advanced gastric cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.902304

Randomised phase II trial of docetaxel and sunitinib in patients with metastatic gastric cancer who were previously treated with fluoropyrimidine and platinum.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.902304

A phase I, dose-finding study of sunitinib combined with cisplatin and 5-fluorouracil in patients with advanced gastric cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.902304

Inhibition of insulin-like growth factor-I receptor (IGF-IR) signaling and tumor cell growth by a fully human neutralizing anti-IGF-IR antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.902304

Targeting the insulin-like growth factor axis for the development of novel therapeutics in oncology

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.902304

Phase 1 study of ganitumab (AMG 479), a fully human monoclonal antibody against the insulin-like growth factor receptor type I (IGF1R), in Japanese patients with advanced solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.902304

The insulin-like growth factor-I receptor inhibitor figitumumab (CP-751,871) in combination with docetaxel in patients with advanced solid tumours: results of a phase Ib dose-escalation, open-label study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.902304

Targeting the c-Met signaling pathway in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.902304

MET expression and amplification in patients with localized gastric cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.902304

MET amplification identifies a small and aggressive subgroup of esophagogastric adenocarcinoma with evidence of responsiveness to crizotinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.902304

MET amplification as a potential therapeutic target in gastric cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.902304

Seminars in clinical pharmacology: an introduction to MET inhibitors for the medical oncologist.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.902304

Phase II study evaluating 2 dosing schedules of oral foretinib (GSK1363089), cMET/VEGFR2 inhibitor, in patients with metastatic gastric cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.902304

mTOR as a therapeutic target in patients with gastric cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.902304

Phase I clinical and pharmacokinetic study of RAD001 (everolimus) administered daily to Japanese patients with advanced solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.902304

Phase I study of everolimus and mitomycin C for patients with metastatic esophagogastric adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.902304

Multicenter phase II study of everolimus in patients with previously treated metastatic gastric cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.902304

Everolimus for previously treated advanced gastric cancer: results of the randomized, double-blind, phase III GRANITE-1 study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.902304

Targeting heat shock proteins 70/90 and proteasome for cancer therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.902304

High expression of heat shock protein 90 is associated with tumor aggressiveness and poor prognosis in patients with advanced gastric cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.902304

High HSP90 expression is associated with decreased survival in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.902304

Hsp90 as a therapeutic target in prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.902304

The ubiquitin-proteasome pathway and its role in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.902304

Antitumor effects and drug interactions of the proteasome inhibitor bortezomib (PS341) in gastric cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.902304

Bortezomib, paclitaxel, and carboplatin as a first-line regimen for patients with metastatic esophageal, gastric, and gastroesophageal cancer: phase II results from the North Central Cancer Treatment Group (N044B).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.902304

A multicenter, phase II study of bortezomib (PS-341) in patients with unresectable or metastatic gastric and gastroesophageal junction adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.902304

In silico identification of poly(ADP-ribose)polymerase-1 inhibitors and their chemosensitizing effects against cisplatin-resistant human gastric cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.902304

ATM-depletion in breast cancer cells confers sensitivity to PARP inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.902304

Roles of Aurora kinases in mitosis and tumorigenesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.902304

Aurora kinase A promotes inflammation and tumorigenesis in mice and human gastric neoplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.902304

Polo-like kinase 1 inhibitors and their potential role in anticancer therapy, with a focus on NSCLC.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.902304

Expression of polo-like kinase 1 (PLK1) protein predicts the survival of patients with gastric carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.902304

Expression patterns of polo-like kinase 1 in human gastric cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.902304

A randomised phase II trial of the Polo-like kinase inhibitor BI 2536 in chemo-naïve patients with unresectable exocrine adenocarcinoma of the pancreas - a study within the Central European Society Anticancer Drug Research (CESAR) collaborative netw

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.902304

An open-label, phase I study of the polo-like kinase-1 inhibitor, BI 2536, in patients with advanced solid tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.902304

Phase II study of the cyclin-dependent kinase inhibitor flavopiridol administered to patients with advanced gastric carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.902304

Phase I study of flavopiridol with oxaliplatin and fluorouracil/leucovorin in advanced solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.902304

The validation of matrix metalloproteinase-9 mRNA gene expression as a predictor of outcome in patients with metastatic gastric cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.902304

Matrix metalloproteinase-9 is required for tumor vasculogenesis but not for angiogenesis: role of bone marrow-derived myelomonocytic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.902304

Marimastat as maintenance therapy for patients with advanced gastric cancer: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.902304

Role of cyclooxygenase-2 in gastric cancer development and progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.902304

Non-steroidal anti-inflammatory drug use and the risk of gastric cancer: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.902304

Aspirin protects against gastric cancer: results of a case-control study from Moscow, Russia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.902304

The trifunctional antibody ertumaxomab destroys tumor cells that express low levels of human epidermal growth factor receptor 2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.902304

The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: Results of a prospective randomized phase II/III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.902304

Claudin-18 gene structure, regulation, and expression is evolutionary conserved in mammals

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.902304

Claudin-18 splice variant 2 is a pan-cancer target suitable for therapeutic antibody development

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.902304

Efficacy of adjuvant immunotherapy with cytokine-induced killer cells in patients with locally advanced gastric cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.902304

Importance of gastrin in the pathogenesis and treatment of gastric tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.902304

Identification of molecular subtypes of gastric cancer with different responses to PI3-kinase inhibitors and 5-fluorouracil

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.902304

Pharmacodynamic Studies of Gefitinib in Tumor Biopsy Specimens From Patients With Advanced Gastric Carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.902304

10.1586/17474124.2014.902304

21 January 2018

Identifiers

DOI

1 reference

30 August 2017

1 reference

PubMed ID

24665840